Navigation Links
Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis
Date:1/11/2010

tract key employees whose knowledge is essential to the development of its products; that unforeseen scientific difficulties develop with the Company's process; that Raptor's patents are not sufficient to protect essential aspects of its technology; that competitors may invent better technology; and that Raptor's products may not work as well as hoped or worse, that the Company's products may harm recipients. As well, Raptor's products may never develop into useful products and even if they do, they may not be approved for sale to the public. Raptor cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the Company's filings from time to time with the Securities and Exchange Commission (the "SEC"), which Raptor strongly urges you to read and consider, including Raptor's current report on Form 8-K as filed with the SEC on November 17, 2009 and the joint proxy statement/prospectus on Form S-4 filed with the SEC on August 19, 2009, all of which are available free of charge on the SEC's web site at http://www.sec.gov. Subsequent written and oral forward-looking statements attributable to Raptor or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in Raptor's reports filed with the SEC. Raptor expressly disclaims any intent or obligation to update any forward-looking statements.


    For more information, please contact:

    Kim R. Tsuchimoto, CFO
    (415) 382-1390
    ktsuchimoto@raptorpharma.com

    The Ruth Group

    Sara Ephraim Pellegrino (investors)
    (646) 536-7002
    spellegrino@theruthgroup.com

    Janine McCargo (media)
    (646) 536-7033
    '/>"/>
SOURCE Raptor Pharmaceutical Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Raptor Pharmaceuticals Provides Update of Product Programs
2. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
3. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
4. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
5. Raptor Pharmaceuticals Provides Update on Targeting Platforms
6. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
7. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
8. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
9. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
10. Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications
11. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014  Edwards Lifesciences Corporation (NYSE: EW ... valves and hemodynamic monitoring, announced today that it will ... a strong launch of Edwards Lifesciences Foundation,s new charitable ... the global communities where its employees live and work. ... will exceed $8 million, including more than $7 million ...
(Date:11/21/2014)... /CNW Telbec/ - KLOX Technologies Inc. ("KLOX" or the ... Todd Martensen has been hired ... of Chief Commercial Officer, to oversee KLOX,s commercial launch ... for the treatment of chronic and other hard-to-heal wounds, ... in Europe . Mr. Martensen, a ...
(Date:11/21/2014)... GABLES, Fla. , Nov. 20, 2014   ... to become the first U.S. commercial producer of Molybdenum-99 ... a contract with INVAP to design its ... Fla. Mo-99 is the parent isotope of ... medicine procedures worldwide. In 2012, Congress passed legislation making ...
Breaking Medicine Technology:Edwards Lifesciences Increases Charitable Giving In 2014 To Support Launch Of Every Heartbeat Matters 2KLOX Technologies announces executive appointments 2KLOX Technologies announces executive appointments 3KLOX Technologies announces executive appointments 4Coqui RadioPharmaceuticals Inks Deal With INVAP 2
... , LAIYANG, China, Nov. 16 /PRNewswire-Asia-FirstCall/ ... "Company"),a U.S. pharmaceutical company with its principal operations in the ... a conference,call at 9:00 a.m. Eastern Time on Wednesday, November ... fiscal year 2010. , Conference Call ...
... , STAMFORD, Conn., Nov. 13 ... will be releasing a free trial version of its Zargis ... conference, taking place this November 15-17 in Orlando. Zargis is ... the companion hardware -- the 3M Littmann Electronic Stethoscope Model ...
Cached Medicine Technology:Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010 2Zargis to Release Trial Version of Cardioscan while Exhibiting with 3M(TM) Littmann(R) at American Heart Association Conference 2Zargis to Release Trial Version of Cardioscan while Exhibiting with 3M(TM) Littmann(R) at American Heart Association Conference 3
(Date:11/21/2014)... November 21, 2014 Body Well Therapy, a ... it accepts Spafinder massage gift cards and ... hotel massage in all service areas including throughout Florida and ... to go to the spa at all to redeem your ... of Body Well. "We may not be able to transport ...
(Date:11/21/2014)... The cost of diabetes care in the United States ... more than $322 billion annually, a new report shows. ... prediabetes care, which have risen 74 percent, and undiagnosed ... In 2012, excess medical costs and lost productivity ... American. That total includes $244 billion in medical costs ...
(Date:11/21/2014)... they,ve mapped the genome -- the genetic "blueprint" -- of ... it might help others with this very rare infection. ... , the tapeworm was removed from the brain of a ... so rare worldwide and completely unexpected in this country that ... pulled out from the brain," study lead author Hayley Bennett, ...
(Date:11/21/2014)... 21, 2014 MLF Biotech, Inc. has ... . Liv-Pro® Probiotics for Pets helps maintain digestive health ... a pet's intestinal flora after it experiences a period ... Liv-Pro Probiotics for Pets is a proprietary blend of ... seven live active bacteria strains that are safe and ...
(Date:11/21/2014)... 21, 2014 Saint Luke’s Mid ... The Guidelines®–Heart Failure Gold-Plus Quality Achievement Award for ... American Heart Association/American College of Cardiology Foundation in ... , Get With The Guidelines–Heart Failure is a ... the most up-to-date, research-based guidelines with the goal ...
Breaking Medicine News(10 mins):Health News:Body Well Mobile Massage Announces Acceptance of Spafinder Gift Cards for In Home Massage, Hotel Massage for Travelers 2Health News:Cost of Diabetes Care Keeps Climbing, Report Shows 2Health News:Ick! Tapeworm Infecting Man's Brain Yields Genetic Secrets 2Health News:MLF Biotech Introduces Liv-Pro Probiotics for Pets 2Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 2Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 3Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 4
... March 7 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ... webcast live during the Cowen & Company 28th ... 8:00 a.m. Eastern Time., The presentation will ... access the live presentation via the Web, please ...
... Affiliated Computer Services,Inc. (NYSE: ACS ) today ... to provide electronic health records and pharmacy,benefits management solutions. ... years,and a total value of $57 million if all ... will provide the state with several components,of ACS, electronic ...
... March 6 Nfocus Neuromedical, Inc.,announced today that ... StarFire Medical is a manufacturer of therapeutic implantable ... The assets acquired include products such as ... Silicone Balloon), also,known as the Endeavor Balloon Catheter, ...
... Webcast Scheduled for March 7, 2008 at 2:00 pm ... Ensign,Group, Inc. (Nasdaq: ENSG ), the parent company ... and assisted living,companies, today reported results for the fourth ... (Logo: http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO ), Highlights ...
... 6 QED International Associates, Inc.,administrator for the ... the HealthShares(TM) Exchange-Traded Funds, today announced,that effective at ... ISIS,Pharmaceuticals (Nasdaq: ISIS ) will replace Pharmion ... Index. Synta Pharmaceuticals Corp.,(Nasdaq: SNTA ) will ...
... A new study suggests that a type of acute ... one small molecule result in the over-activity of genes important ... myeloid leukemia (AML) and a gene mutation called NPM1, an ... The findings suggest new therapeutic targets for treating the disease ...
Cached Medicine News:Health News:Alexza's Corporate Presentation to be Webcast at the Cowen & Company 28th Annual Health Care Conference 2Health News:ACS Announces $57 Million Contract With Missouri HealthNet 2Health News:ACS Announces $57 Million Contract With Missouri HealthNet 3Health News:Nfocus Neuromedical Announces Acquisition of StarFire Medical 2Health News:The Ensign Group, Inc. Reports Fourth Quarter 2007 Earnings 2Health News:The Ensign Group, Inc. Reports Fourth Quarter 2007 Earnings 3Health News:The Ensign Group, Inc. Reports Fourth Quarter 2007 Earnings 4Health News:The Ensign Group, Inc. Reports Fourth Quarter 2007 Earnings 5Health News:The Ensign Group, Inc. Reports Fourth Quarter 2007 Earnings 6Health News:The Ensign Group, Inc. Reports Fourth Quarter 2007 Earnings 7Health News:The Ensign Group, Inc. Reports Fourth Quarter 2007 Earnings 8Health News:QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Cancer Indexes 2Health News:Low micro-RNA level linked to high gene activity in AML 2
... important diagnostic tool ... of a patient's ... important when deciding ... for patients receiving ...
The Karl Storz Videoscope offers maximum image quality and can be used in combination with standard documentation units. In contrast with conventional flexible endoscopes, images are displayed with ...
Maximum brightness, durability, universal power suply, microprocessor-controlled light output and, in the event of lamp failure or degredation, automatic switchover to an integraged spare lamp....
Integrated electronics, single-chip CCD camera with PAL and NTSC output. PAL output at 460 lines, NTSC output at 470 lines. 30mm focal length. 90mm length x 20mm diameter....
Medicine Products: